An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
Pancreatic Cancer|Neoadjuvant
DRUG: Neoadjuvant treatment
Overall survival, the time from diagnosis to death from any cause or the date of the last visit, From the date when biopsy results came out until the date of death from any cause or the date of the last visit, whichever came first, assessed up to 60 months
The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.